Qatar Biomedical Research Institute (QBRI) drives biomedical innovation by translating scientific discoveries into real-world healthcare solutions. Our scientists collaborate across disciplines to develop technologies that address both national and global health priorities.
Through close coordination with Hamad Bin Khalifa University’s Office of Innovation and Industrial Relations (OIIR), QBRI supports advancing promising research toward commercialization. This includes early-stage innovation development, patent protection, industry partnerships, and startup incubation.
To date, QBRI has filed multiple patents and submitted numerous inventions disclosures across key research areas, including neurological, metabolic, and oncological diseases. Our innovations span novel biomarkers, diagnostic assays, and therapeutic targets—designed to improve early detection, disease monitoring, and treatment outcomes.
I Track LLC
As part of QBRI’s commitment to translating research into impactful solutions, it has supported the establishment of I Track LLC, an institute-incubated startup registered under the Qatar Financial Centre. I Track LLC focuses on the development and commercialization of AI-driven digital diagnostic solutions for neurodevelopmental disorders, with a primary focus on Autism Spectrum Disorder (ASD). Leveraging advanced eye-tracking technology and proprietary machine learning algorithms, I Track aims to enable objective, rapid, and scalable assessment and early detection. The platform is designed to support clinical decision-making, accelerate time-to-diagnosis, and expand access to high-quality diagnostic support globally.
QABY
QBRI has supported the establishment of QABY Biotech, reflecting its commitment to translating research into impactful solutions. QABY Biotech is an institute-incubated startup registered under the Qatar Financial Centre. The name ‘QABY’ is a registered trademark of Qatar Foundation. It focuses on developing innovative diagnostic and therapeutic solutions for neurodegenerative diseases, with a particular emphasis on Parkinson’s disease and related diseases. Leveraging proprietary technologies, QABY aims to advance biomarker discovery, enable early and accurate diagnosis, and develop novel therapeutic approaches.
